Literature DB >> 19203722

The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation.

John A Zaia1, Joel Y Sun, Ghislaine M Gallez-Hawkins, Lia Thao, Arisa Oki, Simon F Lacey, Andrew Dagis, Joycelynne Palmer, Don J Diamond, Stephen J Forman, David Senitzer.   

Abstract

It has been shown that activating killer Ig-like receptor (aKIR) genes are important for control of cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation (HCT). To date, using the broad classification of KIR haplotypes A and B, the precise role of individual KIR genes in the control of infection cannot be discerned. To address this, a consecutive case series of 211 non-T cell-depleted HCT patients all at risk for CMV were monitored biweekly for CMV DNA in plasma by quantitative polymerase chain reaction (Q-PCR) and at intervals for CMV-specific T cell immunity. Comparing patients with CMV reactivation (n = 152) to those with no reactivation (n = 59), the presence of specific aKIR haplotypes in the donor, but not in the recipient, were associated with protection from CMV reactivation and control of peak plasma CMV DNA (P < .001). A donor aKIR profile, predictive for low risk of CMV reactivation, contained either aKIR2DS2 and aKIR2DS4 or had >/=5 aKIR genes. Neither donor nor recipient inhibitory KIR (iKIR) played a role in a protective effect. CD4(+)- and CD8(+)-specific CMV immunity did not explain reduced CMV infection. The initial control of CMV infection after HCT is managed by aKIR functions, and donor aKIR haplotypes deserve further evaluation in donor selection for optimized HCT outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203722      PMCID: PMC2770248          DOI: 10.1016/j.bbmt.2008.11.030

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

1.  Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.

Authors:  Katharine C Hsu; Xiao-Rong Liu; Annamalai Selvakumar; Eric Mickelson; Richard J O'Reilly; Bo Dupont
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

2.  Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping.

Authors:  J Y Sun; L Gaidulis; M M Miller; R M Goto; R Rodriguez; S J Forman; D Senitzer
Journal:  Tissue Antigens       Date:  2004-10

Review 3.  In search of the 'missing self': MHC molecules and NK cell recognition.

Authors:  H G Ljunggren; K Kärre
Journal:  Immunol Today       Date:  1990-07

Review 4.  Evolutionary struggles between NK cells and viruses.

Authors:  Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

5.  Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens.

Authors:  C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

6.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

Review 7.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

8.  NK cell functions restrain T cell responses during viral infections.

Authors:  H C Su; K B Nguyen; T P Salazar-Mather; M C Ruzek; M Y Dalod; C A Biron
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

9.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

10.  HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.

Authors:  Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington
Journal:  Science       Date:  2004-08-06       Impact factor: 47.728

View more
  32 in total

1.  An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Authors:  Deborah Wood; Robin Wesselschmidt; Peiman Hematti; Adrian P Gee; Cliona Rooney; Leslie Silberstein; Myriam Armant; Larry Couture; John E Wagner; David H McKenna; Derek Hei; Traci Heath Mondoro; Lisbeth Welniak; Robert Lindblad
Journal:  Clin Transl Sci       Date:  2014-03-21       Impact factor: 4.689

2.  Investigation of deletion of 22pb in KIR2DS4 gene in a population of southern Brazil.

Authors:  Amanda Vansan Marangon; Jeane Eliete Laguila Visentainer; Gláucia Andréia Soares Guelsin; Samaia Laface Clementino; Cristiane Conceição Chagas Rudnick; Fabiano Cavalcante de Melo; Marco Antonio Braga; Ana Maria Sell
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

3.  Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Authors:  K Frenzel; J Lehmann; D H Krüger; L Martin-Parras; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2013-12-15       Impact factor: 3.402

4.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

5.  KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).

Authors:  Ghislaine M Gallez-Hawkins; Xiuli Li; Anne E Franck; Ketevan Gendzekhadze; Ryotaro Nakamura; Stephen J Forman; David Senitzer; John A Zaia
Journal:  Hum Immunol       Date:  2012-08-30       Impact factor: 2.850

6.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

7.  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.

Authors:  Jill C Beck; John E Wagner; Todd E DeFor; Claudio G Brunstein; Mark R Schleiss; Jo-Anne Young; Daniel H Weisdorf; Sarah Cooley; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

Review 8.  Risk stratification and immunogenetic risk for infections following stem cell transplantation.

Authors:  Agnieszka Wójtowicz; Pierre-Yves Bochud
Journal:  Virulence       Date:  2016-09-09       Impact factor: 5.882

9.  KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients.

Authors:  A Gonzalez; K Schmitter; H H Hirsch; C Garzoni; C van Delden; K Boggian; N J Mueller; C Berger; J Villard; O Manuel; P Meylan; M Stern; C Hess
Journal:  Genes Immun       Date:  2014-07-10       Impact factor: 2.676

Review 10.  Hunting for clinical translation with innate-like immune cells and their receptors.

Authors:  W Scheper; C Gründer; T Straetemans; Z Sebestyen; J Kuball
Journal:  Leukemia       Date:  2013-12-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.